Inside Precision Medicine April 17, 2024
Helen Albert

Scopio Labs, an imaging and analysis focused medtech company based in Israel, have received De Novo FDA clearance for its artificial intelligence (AI)-driven bone marrow aspirate analysis software.

Bone marrow samples are important for diagnosing a range of different blood disorders such as different blood cancers, but standard methods of analyzing these samples are time consuming and rely on the skills, knowledge and in-person presence of trained hematopathologists to ensure accuracy.

Scopio produces two machines, one designed for smaller labs and lower throughput and a higher throughput machine, that are able to image blood and other cells in high detail.

The newly approved full-field bone marrow aspirate application uses AI to analyze thousands of cells in each bone marrow sample...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
AI Models Continue to Gain Clinicians’ Attention
Colon-cancer blood test earns safety endorsement from FDA panel
FDA considers 2nd blood test for colon cancer — but advisers note concerns
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
FDA blesses Pfizer with priority review voucher for Paxlovid nod

Share This Article